Business context and reporting period
ICU Medical, Inc. develops, manufactures and sells medical devices for infusion therapy, critical care and oncology. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2016; comparisons are with the corresponding 2015 periods. The company reports one operating segment.
Financial performance and position
Unless noted otherwise, amounts are in millions of dollars.
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Total revenue | $96.7 | $83.8 | $186.6 | $165.3 |
| Gross profit | $50.1 | $43.8 | $99.4 | $86.3 |
| Operating income | $22.8 | $20.3 | $46.7 | $31.3 |
| Net income | $16.6 | $13.6 | $34.8 | $23.3 |
| Diluted EPS | $0.98 | $0.83 | $2.05 | $1.43 |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $41.8 | $29.2 |
Revenue increased 15% in Q2 and 13% year to date; net income increased 22% and 50%, respectively. Gross margin was 51.8% in Q2 (down 0.4 percentage points year over year) and 53.3% year to date (up 1.1 points). Q2 operating margin was approximately 23.5%, versus 24.3% a year earlier; six-month operating margin was 25.0%, versus 18.9%.
Infusion therapy revenue grew 21% in Q2 and 16% year to date, while oncology grew 25% and 29%. Critical care declined 13% in Q2 and 9% year to date. The filing attributes infusion growth mainly to SwabCap and Clave products and oncology growth to direct sales of ChemoLock and ChemoClave. Critical care weakness reflected lower U.S. and international sales of hemodynamic monitoring and closed blood sampling products.
At June 30, cash and cash equivalents were $372.9 million and investment securities were $27.7 million, totaling $400.6 million, up $23.2 million from year-end. Current assets were $535.4 million and current liabilities $40.6 million, implying a current ratio of about 13.2x. Total liabilities included $1.3 million of long-term liabilities; the filing does not clearly identify a separate borrowing or debt balance. Six-month operating cash flow of $41.8 million was up from $29.2 million. Capital expenditures were $9.1 million; financing cash flow included $16.9 million of treasury-stock purchases.
Material changes, outlook and risks
- Results included a $1.1 million bargain-purchase gain from the April acquisition of Tangent Medical Technologies for $2.6 million cash, and $1.5 million of restructuring and strategic-transaction expenses. Tangent makes IV catheters; ICU Medical said significant commercial results were not expected for 18–24 months while it modifies the product.
- Early adoption of stock-compensation accounting guidance generated discrete tax benefits of $0.8 million in Q2 and $3.1 million for the first half. These benefits materially aided reported earnings and reduced the effective tax rate; they are not necessarily recurring. The 2015 comparison included a $7.1 million Hospira legal-settlement charge, paid in 2015.
- Management estimated 2016 capital expenditures of $18–20 million, including manufacturing investment in the U.S. and Mexico and expansion of the Mexico facility in connection with the planned Slovakia plant closure. Sale of the Slovakia facility was expected in the second half of 2016. No specific revenue or EPS guidance was provided. Management expected existing cash, securities and operating cash generation to fund operations for at least 12 months.
- Customer concentration is material: Pfizer/Hospira represented 34% of first-half revenue and 35% of receivables at quarter-end. Related agreements extend through December 2018. Management cautioned that changes in this relationship or customer demand could adversely affect results.
- Other disclosed risks include manufacturing constraints that weighed on Q2 gross margin, execution of the Slovakia closure and Mexico expansion, product development and regulatory outcomes, competition and pricing pressure, and unhedged foreign-exchange exposure. A 10% euro movement was estimated to affect specified balance-sheet items by about $10.8 million. Management said routine legal proceedings were not expected to have a material adverse effect; no material change to previously disclosed risk factors was reported.
Important facts for investors to verify
- Whether infusion and oncology growth can continue and critical care sales stabilize.
- How much earnings growth reflects recurring operations versus the $3.1 million first-half tax benefit and $1.1 million bargain-purchase gain.
- Sales, receivables and agreement developments involving Pfizer/Hospira, including the concentration and contract term.
- Progress, costs and timing of the Slovakia facility sale and Mexico manufacturing expansion; compare actual capex with the $18–20 million estimate.
- Inventory and accrued-liability movements, manufacturing constraints, and currency exposure, including the lack of foreign-exchange hedging.